GLP-1 on Non-ST-Segment Elevation Myocardial Infarction
- Registration Number
- NCT02577848
- Lead Sponsor
- Chinese PLA General Hospital
- Brief Summary
The investigators planned to evaluate the effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction (NSTEMI).
- Detailed Description
Patients with non-ST-segment elevation myocardial infarction (NSTEMI) are a heterogeneous group with respect to the risk of having a major adverse cardiac event (MACE). Elevation of blood glucose is a common metabolic disorder among patients with acute myocardial infarction (AMI) and is associated with adverse prognosis. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose. GLP-1 analogues have significant cardiovascular protective effects in patients with AMI. GLP-1 may have antioxidant and anti-inflammatory properties, and protect endothelial function. Studies in conscious, chronically instrumented dogs demonstrated that GLP-1 infusion increases insulin sensitivity and myocardial glucose uptake in postischemic contractile dysfunction and dilated cardiomyopathy. Liraglutide, a GLP-1 analogue, was reported to reduce cardiac rupture and infarct size and improve cardiac output in normal and diabetic mice. Continuous infusion of GLP-1 (1.5 pmol/kg/min) has been shown to improve functional recovery in patients with AMI complicated by decreased left ventricular function GLP-1 could protect against ischemia-reperfusion injury and improve cardiac function in patients with acute ST-segment elevation myocardial infarction. However, the effects of GLP-1 on NSTEMI patients remain unclear. The aim of this study was to evaluate the effects of liraglutide on left ventricular function in patients with NSTEMI.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 90
non-ST-segment elevation myocardial infarction (NSTEMI )
- unconscious at presentation
- had ST-segment elevation acute myocardial infarction
- NSTEMI requiring emergency percutaneous coronary angiography
- valvular heart disease
- cardiogenic shock
- hypoglycaemia
- diabetic ketoacidosis
- had a history of myocardial infarction
- stent implantation
- renal insufficiency
- had previously undergone coronary artery bypass surgery.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description placebo Placebo placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days. GLP-1 group GLP-1 liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
- Primary Outcome Measures
Name Time Method left ventricular ejection fractions at 3 months The primary efficacy endpoint was the effect of liraglutide on left ventricular ejection fractions (LVEF) measured by transthoracic echocardiography at 3 months .
- Secondary Outcome Measures
Name Time Method 6-minute walk distance at 3 months The change in6-minute walk distance at 3 months after treatment.
treatment-emergent adverse events at 3 months Treatment-emergent adverse events (TEAEs): hypoglycaemia, pancreatitis, thyroid cancer
Trial Locations
- Locations (1)
PLA General Hospital
🇨🇳Beijing, Beijing, China